How India Exports Asava to the World

Asava, being an Ayurvedic medicinal preparation, does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. The FDA has not granted marketing authorization for Asava products, and there are no recent approvals or import alerts specific to Asava. However, the FDA has issued warnings regarding certain unapproved Ayurvedic products containing harmful levels of heavy metals, leading to import alerts for such products. For instance, in June 2025, the FDA issued import alerts for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation due to quality system regulation violations. Given the absence of FDA approval for Asava, Indian exporters must navigate a complex regulatory pathway to enter the U.S. market. This involves ensuring compliance with FDA regulations, including facility registration, product listing, and adherence to Good Manufacturing Practices (GMP). The presence of 86 active Indian exporters indicates a significant interest in exporting Asava; however, the lack of FDA approval poses a substantial barrier to market entry.

In the European Union (EU) and the United Kingdom (UK), medicinal products require marketing authorization from the European Medicines Agency (EMA) or the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Asava, being an Ayurvedic product, falls under the category of traditional herbal medicinal products. To obtain marketing authorization, applicants must demonstrate quality, safety, and efficacy, often through the Traditional Herbal Medicinal Products Directive (2004/24/EC). Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory. As of March 2026, there are no recorded EMA or MHRA actions, approvals, or marketing authorizations for Asava products.

Asava is not included in the World Health Organization's (WHO) Model List of Essential Medicines, which is periodically updated to reflect global health priorities. Consequently, Asava has not undergone WHO Prequalification, a service that assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, Asava is not monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), or European Pharmacopoeia (EP). However, it is recognized in the Indian Pharmacopoeia (IP), which sets quality standards for Ayurvedic medicines in India.

In India, Asava is classified as an Ayurvedic medicine under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. It does not fall under Schedules H, H1, or X, which pertain to allopathic drugs requiring prescription control. The National Pharmaceutical Pricing Authority (NPPA) does not impose a ceiling price on Ayurvedic medicines like Asava, as price control measures primarily target essential allopathic drugs. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations and quality standards.

Asava, being a traditional Ayurvedic formulation, is not subject to patent protection. Its composition and preparation methods are part of the public domain, allowing multiple manufacturers to produce and market the product without exclusivity constraints. This lack of patent protection fosters a competitive market environment, with numerous Indian exporters contributing to the total export value of $0.5 million USD between 2022 and 2026.

In June 2025, the FDA issued import alerts for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation due to quality system regulation violations. In March 2026, the FDA warned consumers about heavy metal poisoning associated with certain unapproved Ayurvedic drug products, highlighting the risks of using products containing harmful levels of heavy metals. These developments underscore the importance of regulatory compliance and quality assurance in the export of Ayurvedic products like Asava.

India's pharmaceutical industry, including the production of "Asava," heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, creating a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and disruptions in Chinese manufacturing.

Recent events have underscored these vulnerabilities. In March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to significant disruptions in global supply chains, affecting the availability and cost of raw materials essential for pharmaceutical manufacturing. Such incidents highlight the critical need for India to diversify its sourcing strategies to mitigate risks associated with overdependence on a single country for essential raw materials.

The export data for "Asava" indicates a high supplier concentration, with the top five exporters accounting for 78.0% of total exports. SAVA HEALTHCARE LIMITED alone holds a 44.8% share, making it the dominant supplier. This concentration poses a significant single-source risk; any operational disruptions at SAVA HEALTHCARE LIMITED could severely impact the global supply of "Asava."

To address such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM manufacturing. This initiative seeks to reduce import dependency and encourage diversification among suppliers. However, the effectiveness of the PLI scheme in mitigating supplier concentration risks remains to be fully realized, as the program is still in its early stages. (pharmanow.live)

The closure of the Strait of Hormuz in March 2026, amid escalating conflicts, has had profound implications for global supply chains. This strategic chokepoint is vital for the transportation of oil and other goods; its blockade has led to increased shipping costs, delays, and heightened risks for maritime operations. Such disruptions have a cascading effect on the pharmaceutical industry, affecting the timely delivery of raw materials and finished products.

Additionally, tensions in the Red Sea and the Strait of Hormuz have further complicated shipping routes, leading to rerouting and additional transit times. These geopolitical challenges underscore the fragility of global supply chains and the need for robust risk mitigation strategies.

• Diversify Supplier Base: Encourage the development of multiple suppliers for "Asava" to reduce dependency on a single exporter, thereby mitigating single-source risks.

• Enhance Domestic Production: Leverage the PLI scheme to bolster domestic manufacturing of APIs and KSMs, reducing reliance on imports and enhancing supply chain resilience.

• Develop Alternative Shipping Routes: Invest in infrastructure and logistics to establish alternative shipping routes that bypass high-risk areas, ensuring continuity in supply chains during geopolitical disruptions.

• Strengthen Inventory Management: Implement robust inventory management practices, including maintaining strategic stockpiles of critical raw materials and finished products to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to continuously monitor geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

RISK_LEVEL: HIGH